Newmanbrain awarded in the IV edition of the rePCV
Newmanbrain was awarded in the IV edition of the rePCV (Valencian Community Scientific Parks network) in the “Best spin-off” category from a pool of 30 other competing companies. It’s been a pleasure to have been able to share our journey with the rePCV and we hope to continue doing so. Newmanbrain has been recognized with […]
Newmanbrain awarded at the I European Artificial Intelligence Forum for its technology for biomedical use.
Newmanbrain, spin-off from the UMH Scientific Park, has recently been awarded at the I European Artificial Intelligence Forum, held in Alicante. ”Pablo Belmonte (Co-founder & CEO) elevator pitch during the I European Artificial Intelligence Forum. / DAVID REVENGA” Newmanbrain received a special prize from the Artificial Intelligence Institute, endowed with a voucher of 4,000 euros. […]
Seal of Excellence 2020 awarded to Newmanbrain
The Seal of Excellence is a quality label first introduced during Horizon 2020, the EU’s research and innovation framework programme (2014-2020). It has gradually become a key instrument to create synergies. The Seal of Excellence is awarded to project proposals submitted under a Horizon Europe call for proposals and ranked above a predefined quality thresholds […]
Newmanbrain winner in the IV edition of the In4Bankia 2019 awards
Newmanbrain has been awarded in the “Best Start-Up” category, aimed at firms with ideas to improve products or services based on new technologies. In4Bankia Award Support the development of Alicante society through the recognition of its most cutting-edge companies. This is the objective of the In4Bankia awards where the Newmanbrain spin-off from the UMH Science […]
Cadena SER’s radio interview to Pablo Belmonte, CEO of Newmanbrain
“Pablo Belmonte, CEO of Newmanbrain, has conducted a radio interview for Cadena Ser during the program “Hoy por Hoy”. We talked about how the company Newmabrain was born as a spin-off of the UMH Scientific Park and about the development of hardware and software for biomedical use, in which Newmanbrain specializes.” Source: https://cadenaser.com/audio/1556099593_452720/
Newmanbrain, spin-off of the Science Park, winner of the V INNOVA eVIA Contest for its technology for biomedical use
The Innova eVIA Awards have recognized the spin-off Newmanbrain from the Scientific Park of the Miguel Hernández University (UMH) of Elche in the “Social-Health Care” category. This company is specialized in the development of software and hardware for biomedical use, mainly in the areas of neuroscience and biomedicine. The Innova eVIA Awards, which on this […]
Newmanbrain, ganadora en la IV edición de los premios In4Bankia 2019
La compañía ha sido galardonada en la categoría “Mejor Start-Up”, dirigida a firmas con ideas para mejorar productos o servicios basados en las nuevas tecnologías.
Newmanbrain’s THEIA™ fNIRs device (formerly known as Brainspy 28) for instant brain performance assessment.
Newmanbrain have created a very light and portable fNIRs device that is placed on the forehead to measure in real time the response of the brain to certain stimuli in adults or children. The new device can help psychologists in the diagnosis and treatment of people with attention deficit disorders, anxiety, hyperactivity or some type […]
Article featuring Newmanbrain and its fNIRs device THEIA™ (former BrainSpy 28) in the Newspaper Information
Diario Información, a newspaper published in the city of Alicante, has made a report on the Newmanbrain team and where Professor Joaquín Ibáñez (Founder and Director of the Project) explains what Newmanbrain is, spin-off of the Miguel Hernandez University of Elche, and its new BrainSpy 28 fNIRs device (now THEIA™) . Source: Diario Información
Newmanbrain, finalist in the IV Innova eVIA Awards for its technology for biomedical use
The spin-off of the UMH Science Park, Newmanbrain, has been chosen as a finalist in the Innova Project category of the IV Innova eVIA Awards Contest. The company has specialized in the development of software and hardware for biomedical use, mainly in the areas of neuroscience and biomedicine. After the first selection of finalists, a […]